Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab + ipilimumab is a combination of two monoclonal antibody therapies used in oncology, particularly studied for metastatic melanoma. Bevacizumab is a humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. Ipilimumab is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), an immune checkpoint receptor on T cells, enhancing the immune system's ability to recognize and destroy cancer cells. The combination aims to simultaneously inhibit tumor angiogenesis and enhance anti-tumor immunity. Clinical studies have shown this regimen can be safely administered with evidence of increased immune cell infiltration into tumors and promising disease control rates in advanced melanoma[1][4].
- Other names
- none
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + ipilimumab.